SCHEMBL4776298

SCHEMBL4776298

[c]1ccc(NCCc2ccccn2)nc1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.69
APP P05067 4/20 0.51
HRH3 Q9Y5N1 1/20 0.50
LMNA P02545 3/20 0.49
ALDH1A1 P00352 3/20 0.49
TAAR1 Q96RJ0 1/20 0.49
ALOX15 P16050 1/20 0.49
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PKM P14618 3/20 0.45
MAPT P10636 1/20 0.45
MKNK1 Q9BUB5 1/20 0.44
CYP2C19 P33261 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
PGK1 P00558 1/20 0.42
HRH1 P35367 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777942 0.84 MAOA (0.53) CYP1A2APPALDH1A1NPC1RAB9A
SCHEMBL27513658 0.82 CYP1A2 (1.00) CYP1A2APPHRH3LMNAALDH1A1
SCHEMBL4774579 0.80 HTR7 (0.46) APPLMNAALDH1A1TAAR1RAB9A
SCHEMBL4769908 0.75 SMN1; SMN2 (0.43) CYP1A2MKNK1CYP2C19PGK1
SCHEMBL19751933 0.75 CYP1A2 (0.84) CYP1A2APPHRH3LMNAALDH1A1
SCHEMBL4775118 0.74 L3MBTL1 (0.47) CYP1A2NPC1RAB9AMKNK1
SCHEMBL29236612 0.73 CYP1A2 (0.70) CYP1A2APPHRH3LMNAALDH1A1
SCHEMBL9093601 0.73 CYP1A2 (0.69) CYP1A2APPHRH3LMNAALDH1A1
SCHEMBL6677526 0.73 CYP1A2 (0.69) CYP1A2APPHRH3LMNAALDH1A1
SCHEMBL31240752 0.73 CYP1A2 (0.69) CYP1A2APPHRH3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A CYP1A2 748/4885APP 1861/4885HRH3 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.